Betaxolol: a pilot study of its pharmacological and therapeutic properties in pregnancy

Boutroy, Marie‐Jeanne; Morselli, P. L.; Bianchetti, G.; Boutroy, J. L.; Pépin, Lucie; Zipfel, Andreas

doi:10.1007/bf00278577

Cited by 5 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preliminary data from studies run in the last 30-60 days of pregnancy suggest that the same can be concluded for the last trimester (Boutroy et al 1990).…”

Section: Discussionmentioning

confidence: 65%

See 1 more Smart Citation

Placental transfer and perinatal pharmacokinetics of betaxolol

Morselli¹,

Boutroy

Bianchetti³

et al. 1990

Eur J Clin Pharmacol

Self Cite

View full text Add to dashboard Cite

Betaxolol levels in blood were monitored in the perinatal period in 28 pregnant hypertensive women and in their babies. In the mothers betaxolol concentrations at delivery ranged from less than 1 to 115 ng.ml-1 after doses of 10 to 40 mg.day-1. The apparent blood half-life was 15.6 to 22.1 h mean (19 h). Umbilical cord levels indicated a rapid equilibrium between fetal and maternal units (ratio 0.93) within few hours after dosing. Milk betaxolol concentrations, measured in few cases, exceeded those in blood by a factor of 3. Amniotic fluid concentrations were similar to those observed in maternal venous blood and umbilical cord blood. In neonates, the blood betaxolol half-life ranged from 14.8 to 38.5 h, with a definite trend towards a negative correlation with gestational age. A 11-61% rise in the betaxolol concentration was observed in 64% of the neonates during the first 12 h of extrauterine life. The data indicate that betaxolol kinetics is not altered in pregnant women and they stress the need for careful and prolonged (72-96 h) intensive monitoring of neonates born to hypertensive mothers treated with beta-blocking agents.

show abstract

“…Preliminary data from studies run in the last 30-60 days of pregnancy suggest that the same can be concluded for the last trimester (Boutroy et al 1990).…”

Section: Discussionmentioning

confidence: 65%

“…The clinical effects of the treatment are reported in detail elsewhere (Boutroy et al 1990). At the last administration preceding delivery, nineteen patients received 10 mg betaxolol, six had 20 mg, two took 30 mg and one received 40 mg.…”

Section: Findings In Mothersmentioning

confidence: 99%

Placental transfer and perinatal pharmacokinetics of betaxolol

Morselli¹,

Boutroy

Bianchetti³

et al. 1990

Eur J Clin Pharmacol

Self Cite

View full text Add to dashboard Cite

show abstract

“…In our study, the metabolite profile of the preterm mice was altered, and differential metabolites were associated with signaling pathways including pyruvate metabolism. Among the top 20 metabolites with the highest VIP scores under POS and NEG modes, respectively, betaxolol has been reported to efficiently treat the arterial hypertension in pregnancy [ 51 , 52 ]. Another metabolite, Arbekacin, is classified as an aminoglycoside antibiotic that exhibits stability against the majority of aminoglycoside-inactivating enzymes.…”

Section: Discussionmentioning

confidence: 99%

Potential roles of the interactions between gut microbiota and metabolites in LPS-induced intrauterine inflammation (IUI) and associated preterm birth (PTB)

Jia,

Tang,

Liu

et al. 2024

J Transl Med

View full text Add to dashboard Cite

Background Prenatal exposure to intrauterine inflammation (IUI) is a crucial event in preterm birth (PTB) pathophysiology, increasing the incidence of neurodevelopmental disorders. Gut microbiota and metabolite profile alterations have been reported to be involved in PTB pathophysiology. Method and results In this study, IUI-exposed PTB mouse model was established and verified by PTB rate and other perinatal adverse reactions; LPS-indued IUI significantly increased the rates of PTB, apoptosis and inflammation in placenta tissue samples. LPS-induced IUI caused no significant differences in species richness and evenness but significantly altered the species abundance distribution. Non-targeted metabolomics analysis indicated that the metabolite profile of the preterm mice was altered, and differential metabolites were associated with signaling pathways including pyruvate metabolism. Furthermore, a significant positive correlation between Parasutterella excrementihominis and S4572761 (Nb-p-coumaroyltryptamine) and Mreference-1264 (pyruvic acid), respectively, was observed. Lastly, pyruvic acid treatment partially improved LPS-induced IUI phenotypes and decreased PTB rates and decreased the apoptosis and inflammation in placenta tissue samples. Conclusion This study revealed an association among gut microbiota dysbiosis, metabolite profile alterations, and LPS-induced IUI and PTB in mice models. Our investigation revealed the possible involvement of gut microbiota in the pathophysiology of LPS-induced IUI and PTB, which might be mediated by metabolites such as pyruvic acid. Future studies should be conducted to verify the findings through larger sample-sized animal studies and clinical investigations.

show abstract

“…Aside from effective HR, BP and MSNA control in hypertension-related tachycardia, therapy with betaxolol has been found favorable in reducing maternal BP without any deleterious effect on the fetus and the newborn [69]. Furthermore, recently a large case-control study in Taiwan found that patients with chronic obstructive pulmonary disease (COPD) taking selective beta-blockers had a lower risk of severe exacerbations compared to patients with COPD who experienced a higher risk of severe exacerbations during an increased mean daily dose of non-cardioselective beta-blockers [70].…”

Section: Effects Of Beta-blockers On Sympathetic Activation In Hypertmentioning

confidence: 99%

Tachycardia: The hidden cardiovascular risk factor in uncomplicated arterial hypertension

Cierpka-Kmieć

Hering

2020

Cardiol J.

View full text Add to dashboard Cite

Early detection and management of elevated blood pressure is crucial in reducing the burden of cardiovascular disease (CVD). The importance of an absolute risk assessment and patient risk stratification has been highlighted in the European hypertension guidelines since 2003. Amongst numerous risk factors influencing patient prognosis, elevated heart rate (HR) has been indicated as important predictor of future risk of hypertension, coronary heart disease, sudden cardiac death, heart failure, CVD, stroke, total cancer and mortality. Given that resting HR can be easily determined in clinical practice and modified by lifestyle changes as well as beta-blocker therapy, it seems reasonable that lowering resting HR should be a potential target to reduce disease burden and premature mortality. However, there is a lack of outcome studies of HR lowering in tachycardia-related hypertension. This review outlines the underlying mechanisms of early course hypertension pathophysiology with the critical role of the sympathetic nervous system activation, the prognostic significance of fast HR and the mechanistic rationale for the use of non-pharmacological approaches and/or highly long-acting cardioselective beta-blockers with some consideration given to betaxolol properties.

show abstract

Betaxolol: a pilot study of its pharmacological and therapeutic properties in pregnancy

Cited by 5 publications

References 24 publications

Placental transfer and perinatal pharmacokinetics of betaxolol

Placental transfer and perinatal pharmacokinetics of betaxolol

Potential roles of the interactions between gut microbiota and metabolites in LPS-induced intrauterine inflammation (IUI) and associated preterm birth (PTB)

Tachycardia: The hidden cardiovascular risk factor in uncomplicated arterial hypertension

Contact Info

Product

Resources

About